Detalhe da pesquisa
1.
Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
J Am Acad Dermatol
; 90(5): 945-952, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38340127
2.
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
N Engl J Med
; 377(16): 1537-1550, 2017 10 19.
Artigo
Inglês
| MEDLINE | ID: mdl-29045212
3.
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Ann Rheum Dis
; 79(11): 1400-1413, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32759265
4.
Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis.
Dermatol Ther (Heidelb)
; 13(4): 951-960, 2023 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-36811773
5.
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial.
J Rheumatol
; 50(4): 478-487, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36379575
6.
Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.
Clin Pharmacol Ther
; 112(3): 665-675, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35344588
7.
A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis.
J Dermatol
; 48(11): 1640-1651, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34435694
8.
Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.
RMD Open
; 7(1)2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33452181
9.
Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.
J Rheumatol
; 46(9): 1089-1096, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30824647
10.
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
RMD Open
; 5(1): e000806, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-30713721
11.
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis.
Inflamm Bowel Dis
; 24(12): 2494-2500, 2018 11 29.
Artigo
Inglês
| MEDLINE | ID: mdl-29982686